carteolol has been researched along with Glaucoma, Suspect in 37 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 9.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 9.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 9.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "004% travoprost and 2% carteolol in patients with ocular hypertension (OHT) after laser peripheral iridotomy (LPI) or trabeculectomy in primary angle-closure glaucoma (PACG)." | 9.17 | [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma]. ( Li, YX; Pang, YY; Yao, BQ, 2013) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 9.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "Carteolol appears to be neutral in its effect on serum lipid levels, whereas timolol maleate adversely affects the HDL and TC/HDL ratio in women age 60 years and older with ocular hypertension or primary open-angle glaucoma." | 9.09 | Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. ( Apostolaros, M; Dubiner, HB; Hudgins, AC; Katz, LJ; Laibovitz, RA; Mundorf, TK; Nussbaum, L; Sall, KN; Shulman, DG; Siegel, LI; Singh, K; Stewart, WC, 1999) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 9.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| "Timolol causes significantly lower mean heart rate during the nighttime and more nocturnal bradycardia than carteolol does in patients with ocular hypertension and primary open-angle glaucoma." | 9.08 | Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, HS, 1997) |
| "Efficacy and safety of ready to use eye drops 2% carteolol-2% pilocarpine combination proved to be comparable to that of eye drops to be reconstituted in the treatment of ocular hypertension poorly controlled by beta-blocker eye drops alone." | 9.08 | [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension]. ( Charlin, JF; Cohn, H; Dascotte, JC; George, JL; Lesure, P; Massin, G; Massin, M; Maurin, JF; Renard, JP; Sirbat, D, 1995) |
| "One hundred seventy-six patients with ocular hypertension or primary open-angle glaucoma were randomly assigned to receive either carteolol 1% twice a day or timolol maleate 0." | 9.08 | Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, H, 1997) |
| "We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0." | 9.06 | A double-masked comparison of carteolol and timolol in ocular hypertension. ( Krieglstein, GK; Mueller, B; Scoville, B; White, BG, 1988) |
| "No significant difference was found between carteolol 1% and 2%, when their effects on intraocular pressure were compared over a 4 week treatment period." | 9.06 | A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. ( Duff, GR, 1987) |
| "Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma." | 7.91 | Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history. ( Jerng, JS; Su, CC; Wu, JH, 2019) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 7.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 5.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 5.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 5.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "004% travoprost and 2% carteolol in patients with ocular hypertension (OHT) after laser peripheral iridotomy (LPI) or trabeculectomy in primary angle-closure glaucoma (PACG)." | 5.17 | [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma]. ( Li, YX; Pang, YY; Yao, BQ, 2013) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 5.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "In this double-masked, randomised, intra-subject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2% LA once daily for 2 months and carteolol 2% regular twice daily for 2 months." | 5.11 | Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. ( Allaire, C; Cochereau, I; Elena, PP; Jaulerry, S; Kovalski, JL; Lablache Combier, M; Renard, P; Siou-Mermet, R; Williamson, W, 2005) |
| " Patients with ocular hypertension or open angle glaucoma (n=151) were randomly assigned to receive either 1% carteolol alginate once daily (AM) or standard 1% carteolol solution twice daily for 2 months." | 5.10 | [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. ( Allaire, C; Nordmann, JP; Romanet, JP; Trinquand, C, 2003) |
| "Carteolol appears to be neutral in its effect on serum lipid levels, whereas timolol maleate adversely affects the HDL and TC/HDL ratio in women age 60 years and older with ocular hypertension or primary open-angle glaucoma." | 5.09 | Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. ( Apostolaros, M; Dubiner, HB; Hudgins, AC; Katz, LJ; Laibovitz, RA; Mundorf, TK; Nussbaum, L; Sall, KN; Shulman, DG; Siegel, LI; Singh, K; Stewart, WC, 1999) |
| " This study was conducted to evaluate the central nervous system (CNS) and plasma lipid profiles associated with timolol maleate and carteolol hydrochloride in postmenopausal black women with primary open-angle glaucoma (POAG) or ocular hypertension." | 5.09 | Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. ( Bartlett, JD; Olivier, M; Pensyl, D; Richardson, T; Whitaker, R; Wilson, MR, 1999) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 5.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| " Patients with ocular hypertension or open angle glaucoma (n=235) were randomly assigned to receive either carteolol alginate once daily [corrected] or standard carteolol solution, twice daily." | 5.09 | Ocular hypotensive efficacy and safety of once daily carteolol alginate. ( Allaire, C; Demailly, P; Trinquand, C, 2001) |
| "One hundred seventy-six patients with ocular hypertension or primary open-angle glaucoma were randomly assigned to receive either carteolol 1% twice a day or timolol maleate 0." | 5.08 | Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, H, 1997) |
| "Timolol causes significantly lower mean heart rate during the nighttime and more nocturnal bradycardia than carteolol does in patients with ocular hypertension and primary open-angle glaucoma." | 5.08 | Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, HS, 1997) |
| "Efficacy and safety of ready to use eye drops 2% carteolol-2% pilocarpine combination proved to be comparable to that of eye drops to be reconstituted in the treatment of ocular hypertension poorly controlled by beta-blocker eye drops alone." | 5.08 | [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension]. ( Charlin, JF; Cohn, H; Dascotte, JC; George, JL; Lesure, P; Massin, G; Massin, M; Maurin, JF; Renard, JP; Sirbat, D, 1995) |
| "5% levobunolol and 2% carteolol were compared in 59 patients with open-angle glaucoma or ocular hypertension." | 5.07 | A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. ( Behrens-Baumann, W; Kimmich, F; Lue, J; Walt, JG, 1994) |
| " Its effect on intraocular pressure and heart rate was tested in a comparison with timolol maleate, as was subjective tolerance of it, in 28 eyes (14 subjects) with either ocular hypertension or simple chronic open-angle glaucoma." | 5.06 | [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops]. ( Flury, H; Martenet, AC; Tournoux, A, 1986) |
| "No significant difference was found between carteolol 1% and 2%, when their effects on intraocular pressure were compared over a 4 week treatment period." | 5.06 | A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. ( Duff, GR, 1987) |
| "We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0." | 5.06 | A double-masked comparison of carteolol and timolol in ocular hypertension. ( Krieglstein, GK; Mueller, B; Scoville, B; White, BG, 1988) |
| "To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma." | 4.31 | Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. ( Kashiwagi, K; Ouchi, K; Shibasaki, Y; Suginaka, M, 2023) |
| " Ophthalmic carteolol eye drops are nonselective beta-blockers and effective against glaucoma and ocular hypertension." | 4.31 | Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops. ( Akashi, R; Eto, R; Ikeda, S; Kawano, H; Maemura, K; Suzuki, A, 2023) |
| "Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma." | 3.91 | Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history. ( Jerng, JS; Su, CC; Wu, JH, 2019) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 3.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| " These dendrimers react with the neutral form of carteolol (an ocular anti-hypertensive drug used to treat glaucoma) to afford ion pair (saline) species." | 3.76 | Designing dendrimers for ocular drug delivery. ( Caminade, AM; Duhayon, C; Elena, PP; Majoral, JP; Malecaze, F; Soler, V; Spataro, G; Turrin, CO, 2010) |
| "5% and carteolol 2% on the blood flow velocity of the central retinal artery (CRA), the posterior ciliary artery (PCA) and the ophthalmic artery (OA) in patients with ocular hypertension." | 3.71 | Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. ( Belcaro, GV; Cesarone, MR; De Sanctis, MT; Incandela, L; Laurora, G; Minicucci, R; Steigerwalt, RD, 2001) |
| "Patients with primary open angle glaucoma and ocular hypertension were randomized to 62 patients of LA group (LA once a day) and 62 patients of CA group (CA twice a day) in this multicenter, open-label trial." | 2.75 | [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration]. ( Ishikawa, Y; Kawase, K; Matsuhisa, A; Migita, M; Muramatsu, T; Nakajima, T; Ono, J; Sugiura, T; Yamamoto, T, 2010) |
| " The dosage forms were tested on intraocular hypertensive-induced rabbits." | 1.29 | Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. ( Hoffman, M; Maincent, P; Marchal-Heussler, L; Sirbat, D, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.22) | 18.7374 |
| 1990's | 11 (29.73) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Eto, R | 2 |
| Kawano, H | 2 |
| Suzuki, A | 2 |
| Akashi, R | 2 |
| Ikeda, S | 2 |
| Maemura, K | 2 |
| Kashiwagi, K | 1 |
| Ouchi, K | 1 |
| Shibasaki, Y | 2 |
| Suginaka, M | 1 |
| Harasymowycz, P | 1 |
| Royer, C | 1 |
| Cui, AX | 1 |
| Barbeau, M | 1 |
| Jobin-Gervais, K | 1 |
| Mathurin, K | 1 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Saito, Y | 1 |
| Kizaki, J | 1 |
| Wada, Y | 1 |
| Kishimoto, N | 1 |
| Aihara, M | 1 |
| Inoue, K | 1 |
| Shiokawa, M | 1 |
| Iwasa, M | 1 |
| Ishida, K | 1 |
| Tomita, G | 1 |
| Soares, RR | 1 |
| Razeghinejad, MR | 1 |
| Wu, JH | 1 |
| Jerng, JS | 1 |
| Su, CC | 1 |
| Yao, BQ | 1 |
| Pang, YY | 1 |
| Li, YX | 1 |
| Yamamoto, T | 4 |
| Ikegami, T | 1 |
| Ishikawa, Y | 2 |
| Kikuchi, S | 1 |
| Spataro, G | 1 |
| Malecaze, F | 1 |
| Turrin, CO | 1 |
| Soler, V | 1 |
| Duhayon, C | 1 |
| Elena, PP | 2 |
| Majoral, JP | 1 |
| Caminade, AM | 1 |
| Zammataro, A | 1 |
| Saletti, R | 1 |
| Civiale, C | 1 |
| Muccilli, V | 1 |
| Cunsolo, V | 1 |
| Foti, S | 1 |
| Kawase, K | 1 |
| Muramatsu, T | 1 |
| Ono, J | 1 |
| Nakajima, T | 1 |
| Matsuhisa, A | 1 |
| Sugiura, T | 1 |
| Migita, M | 1 |
| Trinquand, C | 3 |
| Romanet, JP | 1 |
| Nordmann, JP | 2 |
| Allaire, C | 4 |
| Renard, P | 1 |
| Kovalski, JL | 1 |
| Cochereau, I | 1 |
| Jaulerry, S | 1 |
| Williamson, W | 1 |
| Lablache Combier, M | 1 |
| Siou-Mermet, R | 1 |
| Henness, S | 1 |
| Swainston Harrison, T | 1 |
| Keating, GM | 1 |
| Gorgone, G | 1 |
| Spina, F | 1 |
| Amantia, L | 1 |
| Dascotte, JC | 2 |
| George, JL | 2 |
| Lesure, P | 2 |
| Rouland, JF | 1 |
| Khaitrine, L | 1 |
| Sirbat, D | 3 |
| Frishman, WH | 1 |
| Fuksbrumer, MS | 1 |
| Tannenbaum, M | 1 |
| Behrens-Baumann, W | 1 |
| Kimmich, F | 1 |
| Walt, JG | 1 |
| Lue, J | 1 |
| Marchal-Heussler, L | 1 |
| Hoffman, M | 1 |
| Maincent, P | 1 |
| Charlin, JF | 1 |
| Cohn, H | 1 |
| Massin, M | 1 |
| Massin, G | 1 |
| Maurin, JF | 1 |
| Renard, JP | 1 |
| Kitazawa, Y | 1 |
| Noma, A | 1 |
| Maeda, S | 1 |
| Kato, A | 1 |
| Ando, Y | 1 |
| Ido, T | 1 |
| Inazumi, K | 1 |
| Hayakawa, T | 1 |
| Goto, Y | 1 |
| Ichien, M | 1 |
| Netland, PA | 2 |
| Weiss, HS | 1 |
| Stewart, WC | 3 |
| Cohen, JS | 2 |
| Nussbaum, LL | 2 |
| Weiss, H | 1 |
| Dubiner, HB | 1 |
| Mundorf, TK | 1 |
| Laibovitz, RA | 1 |
| Sall, KN | 1 |
| Katz, LJ | 1 |
| Singh, K | 1 |
| Shulman, DG | 1 |
| Siegel, LI | 1 |
| Hudgins, AC | 1 |
| Nussbaum, L | 1 |
| Apostolaros, M | 1 |
| Bartlett, JD | 1 |
| Olivier, M | 1 |
| Richardson, T | 1 |
| Whitaker, R | 1 |
| Pensyl, D | 1 |
| Wilson, MR | 1 |
| Mirza, GE | 1 |
| Karaküçük, S | 1 |
| Temel, E | 1 |
| Demailly, P | 1 |
| Dahlmann, AH | 1 |
| Benson, MT | 1 |
| Steigerwalt, RD | 1 |
| Laurora, G | 1 |
| Belcaro, GV | 1 |
| Cesarone, MR | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Minicucci, R | 1 |
| Weber, U | 1 |
| Bähr, C | 1 |
| Michaelis, L | 1 |
| Mayer, H | 1 |
| Wirth, K | 1 |
| Scoville, B | 1 |
| Mueller, B | 1 |
| White, BG | 1 |
| Krieglstein, GK | 1 |
| Duff, GR | 2 |
| Graham, PA | 1 |
| Schnaudigel, OE | 1 |
| Becker, H | 1 |
| Fuchs, HB | 1 |
| Flury, H | 1 |
| Tournoux, A | 1 |
| Martenet, AC | 1 |
3 reviews available for carteolol and Glaucoma, Suspect
| Article | Year |
|---|---|
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Topics: Amides; Antihypertensive Agents; Bayes Theorem; Betaxolol; Bimatoprost; Brimonidine Tartrate; Carteo | 2022 |
Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Clinical Trials as Topic; Glaucoma; Humans; Instillati | 2007 |
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Levobu | 1994 |
23 trials available for carteolol and Glaucoma, Suspect
| Article | Year |
|---|---|
Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.
Topics: Antihypertensive Agents; Carteolol; Cross-Over Studies; Drug Combinations; Glaucoma, Open-Angle; Hum | 2021 |
[Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma].
Topics: Aged; Aged, 80 and over; Carteolol; Cloprostenol; Female; Glaucoma, Angle-Closure; Humans; Intraocul | 2013 |
Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Dos | 2016 |
[Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intrao | 2010 |
[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carteolol; Delayed-Action Preparations; | 2003 |
Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carteolol; Cross-Over Studies; Delayed-Action | 2005 |
[Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
Topics: Adrenergic beta-Antagonists; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; | 2007 |
Carteolol: preliminary study on ocular pressure-reducing action.
Topics: Adult; Aged; Carteolol; Clinical Trials as Topic; Female; Glaucoma, Open-Angle; Humans; Intraocular | 1983 |
[Hypotensive action of 0.5% carteolol versus 0.1% timolol in patients with intraocular hypertension].
Topics: Adult; Carteolol; Double-Blind Method; Female; Humans; Male; Ocular Hypertension; Prospective Studie | 1995 |
A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Carteolol; Child; Double-Blind | 1994 |
[Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Double-Blind Method; Drug Combinations; Female; Glauco | 1995 |
The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carteolol; Cholesterol; Cholesterol, HDL; Female; Glaucoma | 1996 |
Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Blood Pressure Mo | 1997 |
Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carteolol; Double-Blind Met | 1997 |
Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carteolol; Double-Blind Method; Female; Glauco | 1999 |
Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women.
Topics: Adrenergic beta-Antagonists; Aged; Black People; Brain; Carteolol; Double-Blind Method; Female; Glau | 1999 |
Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocul | 2000 |
Ocular hypotensive efficacy and safety of once daily carteolol alginate.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Alginates; Analysis of Vari | 2001 |
Carteolol incorporated into FAT-MLV liposomes: prolonged and decreased reduction of IOP.
Topics: Carteolol; Cataract Extraction; Double-Blind Method; Drug Carriers; Humans; Intraocular Pressure; Le | 1992 |
A double-masked comparison of carteolol and timolol in ocular hypertension.
Topics: Administration, Topical; Ambulatory Care; Carteolol; Clinical Trials as Topic; Drug Administration S | 1988 |
A double-crossover trial comparing the effects of topical carteolol and placebo on intraocular pressure.
Topics: Administration, Topical; Carteolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1988 |
A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.
Topics: Carteolol; Clinical Trials as Topic; Humans; Intraocular Pressure; Ocular Hypertension; Propanolamin | 1987 |
[Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops].
Topics: Adult; Aged; Carteolol; Double-Blind Method; Female; Glaucoma; Glaucoma, Open-Angle; Heart Rate; Hum | 1986 |
11 other studies available for carteolol and Glaucoma, Suspect
| Article | Year |
|---|---|
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions.
Topics: Antihypertensive Agents; Carteolol; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ocular Hype | 2023 |
Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Drug Combinations; Drug Substitu | 2018 |
Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Carteolol; Drug Therapy, Combination; Female; Glaucoma; Humans; Latanoprost | 2018 |
Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history.
Topics: Administration, Ophthalmic; Adrenergic beta-Antagonists; Asthma; Bronchoconstriction; Carteolol; Hum | 2019 |
Designing dendrimers for ocular drug delivery.
Topics: Animals; Carboxylic Acids; Carteolol; Dendrimers; Drug Administration Schedule; Drug Carriers; Drug | 2010 |
Simultaneous quantification of carteolol and dorzolamide in rabbit aqueous humor and ciliary body by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Carteolol; Chromatography, High Pressure Liquid; Ci | 2010 |
Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
Topics: Animals; Blood Pressure; Capsules; Carteolol; Chemical Phenomena; Chemistry, Physical; Heart Rate; H | 1993 |
Spontaneous hyphema secondary to iris vascular tufts.
Topics: Aged; Anti-Inflammatory Agents; Atropine; Betamethasone; Carteolol; Drug Therapy, Combination; Human | 2001 |
Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Carte | 2001 |
[Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
Topics: Carteolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Propanolamines | 1988 |